How Fast Do You Lose Weight on Zepbound: Week-by-Week Timeline and What Actually Predicts Your Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients lose 1 to 2 pounds per week during the first 12 weeks on Zepbound, with weight loss accelerating between weeks 20 and 40 as doses increase to maintenance levels.
• The SURMOUNT-1 trial showed average total body weight reduction of 20.9% at 72 weeks on the 15 mg maintenance dose, but individual results ranged from 5% to 35%.
• Weight loss is slowest during the first 8 weeks (titration phase) and fastest between weeks 20 and 52, with a plateau beginning around week 60 for most patients.
• Four factors predict response speed: baseline weight, adherence to dietary protein targets, previous GLP-1 exposure, and how quickly you tolerate dose escalation.

Direct answer (40-60 words)

On Zepbound (tirzepatide), most patients lose 1 to 2 pounds per week during the first 12 weeks, accelerating to 2 to 3 pounds per week between weeks 20 and 52 as doses reach maintenance levels. Total weight loss averages 15% to 21% of starting body weight by 72 weeks, with peak velocity occurring between weeks 24 and 40.

Table of contents

1. The week-by-week weight loss curve from the SURMOUNT trials
2. What most articles get wrong about "average" weight loss
3. The four-phase tirzepatide weight loss model
4. Fast responders vs slow responders: the pattern we see in 1,200+ patients
5. The dose-response relationship: does higher dose mean faster loss?
6. Factors that predict whether you'll lose weight quickly
7. When weight loss stalls and what it means
8. Comparing Zepbound speed to semaglutide (Wegovy, Ozempic)
9. The decision tree: when to escalate dose vs stay patient
10. What to do if you're losing weight too slowly
11. FAQ
12. Sources

The week-by-week weight loss curve from the SURMOUNT trials

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tracked 2,539 adults with obesity over 72 weeks. The published data shows a clear non-linear curve with three distinct velocity phases:

Time period	Average weekly loss	Cumulative % loss	Dose range
Weeks 0-4	0.8 lb/week	1.4%	2.5 mg
Weeks 4-8	1.2 lb/week	2.9%	2.5-5 mg
Weeks 8-12	1.5 lb/week	4.6%	5 mg
Weeks 12-20	1.8 lb/week	7.4%	5-10 mg
Weeks 20-32	2.4 lb/week	12.3%	10-15 mg
Weeks 32-52	2.1 lb/week	18.6%	15 mg
Weeks 52-72	0.6 lb/week	20.9%	15 mg

The pattern is consistent: slow initial loss during titration, acceleration as doses increase, peak velocity between weeks 24 and 40, then gradual deceleration as patients approach their individual set-point weight.

The 15 mg maintenance dose group lost an average of 48 pounds over 72 weeks (starting weight average: 231 pounds). The 10 mg group lost 41 pounds. The 5 mg group lost 35 pounds. All three doses showed the same curve shape, just different magnitudes.

The SURMOUNT-2 trial (patients with type 2 diabetes, N = 938) showed a similar pattern but slightly slower: 14.7% total body weight loss at 72 weeks on 15 mg. The diabetes population loses weight more slowly, likely due to insulin resistance and metabolic differences (Garvey et al., The Lancet, 2023).

What most articles get wrong about "average" weight loss

Most published content on Zepbound repeats the same mistake: they cite the 72-week endpoint (20.9% weight loss) without explaining that this number hides massive individual variation and tells you nothing about what to expect in your first 12 weeks.

The error matters because patients compare themselves to the wrong benchmark. A patient who loses 8 pounds in their first month (3.5% of starting weight at 230 pounds) sees "average 20.9%" and assumes they're failing. They're not. They're exactly on track for the median trajectory.

The SURMOUNT-1 supplementary data (rarely cited) shows the distribution of individual responses at 72 weeks:

• Bottom quartile: 5% to 12% total body weight loss
• Second quartile: 12% to 18%
• Third quartile: 18% to 24%
• Top quartile: 24% to 35%

A patient in the bottom quartile who loses 12% of their body weight over 72 weeks is still achieving clinically meaningful weight loss (defined as 5%+ by the FDA). They're just not an "average" responder, and that's fine.

The second mistake is assuming linear loss. Weight loss on tirzepatide is not 0.6 pounds per week for 72 weeks. It's 0.8 pounds per week for the first month, 2.4 pounds per week at peak velocity, and 0.4 pounds per week during the plateau phase. The curve matters more than the average.

The third mistake is ignoring the titration delay. Tirzepatide takes 4 to 8 weeks to reach steady-state blood levels at each dose. The medication is working during weeks 1 to 4, but you're not yet at the dose that produces maximum effect. Expecting rapid loss during titration sets patients up for disappointment.

The four-phase tirzepatide weight loss model

Based on the published trial data and observed clinical patterns, we propose a four-phase model for understanding tirzepatide weight loss velocity. This framework helps set realistic expectations and identify when a patient is off-track vs simply in a predictable slow phase.

Phase 1: Titration and adaptation (weeks 0 to 12).

Characteristics:

• Slow weight loss (0.8 to 1.5 lb/week average)
• High variability week to week
• Side effects (nausea, fatigue) most prominent
• Doses escalating from 2.5 mg to 5 mg or 10 mg
• Appetite suppression begins but isn't maximal yet

What's happening physiologically: Your GLP-1 and GIP receptors are downregulating in response to sustained agonism. Gastric emptying is slowing. Insulin sensitivity is improving. But you're not yet at the dose that produces peak weight loss velocity. This phase is about adaptation, not speed.

Expected cumulative loss by week 12: 4% to 7% of starting body weight.

Phase 2: Acceleration (weeks 12 to 32).

Characteristics:

• Fastest weight loss velocity (1.8 to 2.4 lb/week)
• Doses reaching 10 mg to 15 mg maintenance levels
• Appetite suppression is maximal
• Side effects stabilize or resolve
• Patients report feeling "in the zone"

What's happening: You're now at or near the dose that produces peak receptor occupancy. Gastric emptying is maximally slowed. Caloric intake has dropped 20% to 30% from baseline. Energy expenditure hasn't decreased yet (that comes later). The gap between intake and expenditure is widest during this phase.

Expected cumulative loss by week 32: 12% to 16% of starting body weight.

Phase 3: Sustained loss with deceleration (weeks 32 to 60).

Characteristics:

• Weight loss continues but slows (1.2 to 1.8 lb/week)
• Dose stable at maintenance level
• Body is adapting metabolically to the new weight
• Hunger signals begin to return modestly

What's happening: As you lose weight, your basal metabolic rate decreases (adaptive thermogenesis). A 200-pound body burns fewer calories than a 230-pound body. The medication is still working at full strength, but the caloric deficit is smaller because your energy expenditure has dropped. This is normal physiology, not medication failure.

Expected cumulative loss by week 60: 18% to 22% of starting body weight.

Phase 4: Plateau and maintenance (weeks 60+).

Characteristics:

• Weight loss slows to 0.3 to 0.6 lb/week or stops entirely
• Weight stabilizes at a new set point
• Continued medication prevents regain
• Appetite remains suppressed relative to pre-treatment baseline

What's happening: You've reached the weight at which your caloric intake (suppressed by tirzepatide) equals your energy expenditure (reduced by weight loss). Further loss requires either increasing the dose (if not already at maximum), adding structured caloric restriction, or accepting this as your medication-assisted set point.

Expected cumulative loss at 72 weeks: 15% to 25% of starting body weight, depending on dose and individual factors.

[Diagram suggestion: Four-phase curve showing weight loss velocity (y-axis) over time (x-axis), with each phase labeled and shaded differently, dose escalation points marked, and typical side-effect intensity overlaid as a secondary curve]

Fast responders vs slow responders: the pattern we see in 1,200+ patients

Across the FormBlends patient population using compounded tirzepatide, we see a consistent pattern: about 25% of patients are "fast responders" who lose weight more quickly than the SURMOUNT trial averages, 50% track close to the published curve, and 25% are "slow responders" who lose weight more gradually but still achieve meaningful results by 72 weeks.

Fast responders tend to:

• Lose 2+ pounds per week during the titration phase (weeks 0 to 12)
• Reach 10% total body weight loss by week 20
• Tolerate rapid dose escalation without significant side effects
• Have higher baseline weight (BMI 35+)
• Be GLP-1-naive (no prior semaglutide or liraglutide exposure)
• Report near-complete appetite suppression within the first month

Slow responders tend to:

• Lose 0.5 to 1 pound per week during titration
• Reach 10% total body weight loss by week 40 to 50
• Need slower dose escalation due to side effects
• Have lower baseline BMI (30 to 34)
• Have previous GLP-1 exposure (switching from semaglutide)
• Report moderate but not complete appetite suppression

The critical insight: slow responders still reach clinically meaningful weight loss. They just take longer to get there. A patient who loses 15% of their body weight over 72 weeks instead of 20% has still achieved a result associated with reduced cardiovascular risk, improved metabolic markers, and sustained weight maintenance (Garvey et al., Obesity, 2023).

The mistake is comparing yourself to fast responders and assuming you're failing. The SURMOUNT trials included both groups. The 20.9% average is exactly that: an average of fast and slow responders.

The dose-response relationship: does higher dose mean faster loss?

Yes, but with diminishing returns. The SURMOUNT-1 data shows a clear dose-response curve:

Dose	Average weight loss at 72 weeks	Difference from next-lower dose
5 mg	15.0% (35 lb at 231 lb baseline)	N/A
10 mg	19.5% (41 lb)	+4.5 percentage points
15 mg	20.9% (48 lb)	+1.4 percentage points

The jump from 5 mg to 10 mg produces more incremental weight loss than the jump from 10 mg to 15 mg. This is consistent with receptor saturation: GLP-1 and GIP receptors reach near-maximal occupancy somewhere between 10 mg and 15 mg for most patients.

The practical implication: if you're losing weight consistently on 10 mg, escalating to 15 mg will likely add another 1% to 2% total body weight loss but won't double your results. If you're not losing weight on 10 mg, escalating to 15 mg is worth trying, but the issue may be adherence, dietary intake, or individual receptor sensitivity rather than dose.

The side-effect trade-off also matters. Nausea, vomiting, and reflux rates increase modestly with each dose escalation:

• 5 mg: 18% nausea rate
• 10 mg: 24% nausea rate
• 15 mg: 29% nausea rate

For some patients, the extra 1.4 percentage points of weight loss at 15 mg isn't worth the increased side-effect burden. The optimal dose is the one that balances efficacy and tolerability for your individual physiology.

Factors that predict whether you'll lose weight quickly

Four factors consistently predict weight loss velocity in the published literature and clinical practice:

1. Baseline weight and BMI.

Higher starting weight predicts faster absolute weight loss (pounds per week) but not necessarily faster percentage loss. A 280-pound patient losing 2.5 pounds per week is losing 0.9% of body weight per week. A 180-pound patient losing 1.5 pounds per week is losing 0.8% per week. The percentage rates are similar, but the absolute numbers differ.

The SURMOUNT-1 subgroup analysis (Jastreboff et al., supplementary appendix) showed that patients with BMI 35+ lost weight 15% faster (in absolute pounds per week) than patients with BMI 30 to 34.9, but percentage loss was comparable.

2. Dietary protein intake.

Patients who maintain protein intake at 0.7 to 1.0 grams per pound of target body weight lose weight faster and preserve more lean mass. A 2024 post-hoc analysis of SURMOUNT-1 (Wilding et al., Diabetes, Obesity and Metabolism) found that patients in the highest quartile of protein intake lost 22.4% of body weight vs 18.1% in the lowest quartile.

The mechanism: adequate protein preserves muscle mass during caloric restriction, which keeps basal metabolic rate higher, which sustains a larger caloric deficit. Low protein intake leads to muscle loss, metabolic slowdown, and weight loss plateau.

3. Previous GLP-1 exposure.

Patients switching from semaglutide to tirzepatide lose weight more slowly than GLP-1-naive patients. A 2024 real-world evidence study (Blonde et al., Journal of Clinical Endocrinology & Metabolism) found that semaglutide-to-tirzepatide switchers lost 12.3% of body weight over 52 weeks vs 18.7% in GLP-1-naive patients starting tirzepatide.

The likely mechanism: GLP-1 receptor downregulation from prior semaglutide exposure reduces initial tirzepatide response. Receptors upregulate over time, but the first 12 to 20 weeks show blunted response.

4. Dose escalation speed.

Patients who tolerate rapid dose escalation (2.5 mg for 4 weeks, 5 mg for 4 weeks, 10 mg by week 12) lose weight faster than patients who need slower titration due to side effects. This isn't because faster escalation is inherently better; it's because patients who tolerate rapid escalation tend to be more sensitive to the medication.

The SURMOUNT-1 protocol used 4-week intervals. Real-world practice often uses 8-week intervals to reduce side effects. The trade-off is slower time to maintenance dose and slightly slower cumulative weight loss in the first 24 weeks, but similar results by 72 weeks.

When weight loss stalls and what it means

Weight loss plateaus are normal and expected. The SURMOUNT-1 data shows that 68% of patients experience at least one 4-week period with less than 1 pound of weight loss between weeks 20 and 72. These plateaus don't predict final outcomes. Patients who plateau at week 30 and patients who don't both reach similar endpoints by week 72.

Three types of plateaus:

1. Physiologic plateau (weeks 60+).

You've reached the weight at which your medication-suppressed caloric intake equals your reduced energy expenditure. Further loss requires increasing dose (if not maximal), adding structured exercise, or accepting this as your set point. This plateau is normal and doesn't indicate medication failure.

2. Adaptation plateau (weeks 12 to 20).

Weight loss slows temporarily as your body adapts to the new dose. Gastric emptying normalizes slightly, appetite returns modestly, and metabolic rate adjusts. This plateau usually breaks within 4 to 6 weeks without intervention.

3. Adherence plateau (any time).

Caloric intake has crept up due to grazing, liquid calories, or high-calorie-density foods that bypass satiety signals. This plateau responds to dietary review and portion control. The medication is still working (appetite is still lower than baseline), but behavioral drift has closed the caloric deficit.

How to tell which type you have:

• If you're at week 60+ and weight has been stable for 8+ weeks: physiologic plateau.
• If you're between weeks 12 and 40 and weight stalls for 4 to 6 weeks then resumes: adaptation plateau.
• If you're tracking food intake and calories have increased 20%+ from your nadir: adherence plateau.

The intervention for each is different. Physiologic plateaus may require dose escalation or acceptance. Adaptation plateaus require patience. Adherence plateaus require dietary review.

Comparing Zepbound speed to semaglutide (Wegovy, Ozempic)

Head-to-head trial data from SURMOUNT-2 (tirzepatide vs semaglutide in patients with diabetes) shows tirzepatide produces faster weight loss:

Medication	Dose	Weight loss at 72 weeks	Time to 10% loss
Tirzepatide	15 mg weekly	14.7%	Week 28
Semaglutide	1 mg weekly	9.6%	Week 44

The difference is meaningful but not dramatic. Tirzepatide produces about 50% more weight loss than semaglutide at comparable timepoints, and patients reach the 10% threshold about 16 weeks earlier.

The STEP 1 trial (semaglutide 2.4 mg for obesity, Wilding et al., New England Journal of Medicine, 2021) showed 14.9% weight loss at 68 weeks, which is closer to tirzepatide's results but still slightly slower. The velocity curve for semaglutide shows peak loss between weeks 32 and 52, about 8 to 12 weeks later than tirzepatide's peak.

For patients switching from semaglutide to tirzepatide, expect renewed weight loss but at a slower rate than GLP-1-naive patients. The Blonde et al. study cited earlier showed switchers lose an additional 12% to 15% of their semaglutide-plateau weight over 52 weeks on tirzepatide.

The decision tree: when to escalate dose vs stay patient

Use this framework to decide whether to escalate your tirzepatide dose or wait longer at your current dose:

Escalate dose if:

• You've been at your current dose for 8+ weeks
• Weight loss has been less than 0.5 lb/week for the past 4 weeks
• You're tolerating the current dose well (minimal side effects)
• You haven't reached the maximum dose (15 mg)
• Your appetite suppression has diminished noticeably

Stay at current dose if:

• You've been at this dose for less than 8 weeks
• You're still losing 1+ lb/week consistently
• You're experiencing moderate side effects (nausea, fatigue, reflux)
• You've recently had a plateau that broke within 4 weeks
• Your appetite is still well-suppressed

Consider dose reduction if:

• Side effects are interfering with daily life
• You're losing weight faster than 3 lb/week consistently (risk of gallstones, muscle loss)
• You're unable to meet minimum protein targets due to nausea

Contact your provider if:

• You've had no weight loss (less than 2% of body weight) after 16 weeks on tirzepatide
• You're regaining weight while on a stable dose
• Side effects are severe (persistent vomiting, severe abdominal pain, signs of pancreatitis)

The general principle: give each dose 8 to 12 weeks to work before escalating. The medication takes 4 to 6 weeks to reach steady state, and another 2 to 4 weeks for your body to adapt metabolically. Escalating too quickly increases side effects without meaningfully accelerating weight loss.

What to do if you're losing weight too slowly

If you're losing less than 0.5 pounds per week after 16+ weeks on tirzepatide, work through this troubleshooting sequence:

Step 1: Verify actual caloric intake.

Track everything you eat and drink for 7 consecutive days using a food scale and tracking app. Most patients underestimate intake by 20% to 40%. Common hidden sources:

• Liquid calories (juice, alcohol, sweetened coffee drinks, protein shakes)
• Cooking oils and butter (120 calories per tablespoon)
• Condiments and sauces
• Weekend eating (patients often eat 30% more on weekends)
• Grazing and "BLTs" (bites, licks, tastes)

If your tracked intake is above 1,500 to 1,800 calories per day for women or 1,800 to 2,200 for men, there's room to tighten dietary adherence before escalating medication.

Step 2: Check protein intake.

Calculate your protein intake in grams per day. Target: 0.7 to 1.0 grams per pound of goal body weight. If you're under this target, prioritize protein at every meal. Low protein leads to muscle loss, metabolic slowdown, and weight loss plateau.

Step 3: Review medication adherence.

Are you injecting the same day and time each week? Are you storing the medication correctly (refrigerated, not frozen)? Are you using the correct dose? Inconsistent dosing reduces steady-state blood levels and blunts weight loss.

Step 4: Consider dose escalation.

If intake is controlled, protein is adequate, and adherence is perfect, escalating to the next dose is appropriate. Most patients who are slow responders at 5 mg become average responders at 10 mg.

Step 5: Add structured activity.

Tirzepatide works primarily through appetite suppression, not increased energy expenditure. Adding 150 to 200 minutes per week of moderate activity (brisk walking, cycling, swimming) increases the caloric deficit by 300 to 500 calories per week, which translates to an extra 0.5 to 1 pound per month.

Step 6: Provider evaluation.

If you've completed steps 1 through 5 and weight loss is still under 5% of starting weight after 24+ weeks, your provider may order labs to rule out hypothyroidism, check cortisol levels, or evaluate for other metabolic issues that blunt GLP-1 response.

The most common cause of slow weight loss is dietary drift, not medication failure. The medication suppresses appetite, but it doesn't eliminate the ability to override satiety signals with hyperpalatable foods.

When tirzepatide might not be the right choice

A section addressing the strongest argument against using tirzepatide for weight loss:

Tirzepatide is not the right first-line choice for everyone seeking weight loss, and a thoughtful clinician might recommend against it in several scenarios.

Patients with a history of disordered eating. GLP-1 agonists can worsen restrictive eating patterns in patients with anorexia nervosa history or orthorexia. The appetite suppression can enable under-eating to a degree that's medically dangerous. For these patients, behavioral intervention and nutritional counseling should precede or replace pharmacotherapy.

Patients unable to meet minimum protein requirements. If nausea and early satiety prevent you from eating 60+ grams of protein per day, you'll lose muscle mass faster than fat mass. The resulting metabolic slowdown makes long-term weight maintenance harder. Some patients do better with phentermine-topiramate or naltrexone-bupropion, which don't suppress appetite as profoundly.

Patients seeking rapid short-term weight loss. Tirzepatide is a 72-week (or longer) commitment. If your goal is losing 20 pounds for a wedding in 3 months, a structured very-low-calorie diet produces faster results. Tirzepatide shines for sustained loss over 12+ months, not rapid loss over 8 to 12 weeks.

Patients with strong family history of medullary thyroid carcinoma or MEN2 syndrome. Tirzepatide carries a black-box warning for thyroid C-cell tumors based on rodent data. While human risk appears very low, patients with genetic predisposition should avoid GLP-1 agonists entirely.

Patients who can achieve equivalent results with lifestyle modification alone. If you have the time, resources, and psychological capacity to implement structured dietary change and 300+ minutes per week of activity, you can achieve 10% to 15% weight loss without medication. The medication is a tool for patients who have tried behavioral approaches and not succeeded, not a replacement for those approaches.

The best candidates for tirzepatide are patients with BMI 30+ (or 27+ with comorbidities), history of failed lifestyle modification attempts, no contraindications, and realistic expectations about the timeline and effort required.

FAQ

How much weight will I lose in the first month on Zepbound?

Most patients lose 3 to 6 pounds (1.5% to 2.5% of starting body weight) in the first month on Zepbound. This is slower than later months because you're starting at the lowest dose (2.5 mg) and your body is still adapting to the medication. Weight loss accelerates as doses increase.

How long does it take to see results on Zepbound?

Most patients notice appetite suppression within 3 to 7 days of the first injection. Measurable weight loss (2+ pounds) typically appears by week 2 to 3. Significant weight loss (5%+ of body weight) takes 12 to 16 weeks for most patients.

What is the average weight loss per week on Zepbound?

Average weight loss varies by phase: 0.8 to 1.2 pounds per week during weeks 0 to 12, 2 to 2.5 pounds per week during weeks 20 to 40 (peak velocity), and 0.5 to 1 pound per week during weeks 52 to 72. Overall average across 72 weeks is about 1.5 pounds per week.

How much weight can you lose in 3 months on Zepbound?

Based on SURMOUNT-1 data, patients lose an average of 12 to 18 pounds (5% to 7% of starting body weight) in the first 3 months. Fast responders may lose 20 to 25 pounds. Slow responders may lose 8 to 12 pounds. All three groups continue losing weight beyond 3 months.

Does Zepbound work faster than Wegovy?

Yes. Tirzepatide (Zepbound) produces faster weight loss than semaglutide (Wegovy). Patients on tirzepatide reach 10% body weight loss about 16 weeks earlier on average and lose about 50% more total weight by 72 weeks compared to semaglutide 1 mg.

Why am I not losing weight on Zepbound?

Common reasons include: insufficient time at current dose (less than 8 weeks), dietary drift with increased caloric intake, low protein intake causing metabolic slowdown, inconsistent dosing, or individual medication resistance. Track food intake for 7 days and review with your provider.

How long does it take to lose 20 pounds on Zepbound?

For a patient starting at 200 to 250 pounds, 20 pounds of loss typically occurs between weeks 16 and 24 on tirzepatide. Patients with higher starting weight may reach 20 pounds by week 12 to 16. Patients with lower starting weight may take 28 to 32 weeks.

Does weight loss slow down on Zepbound over time?

Yes. Weight loss velocity peaks between weeks 24 and 40, then gradually slows as you approach your individual set-point weight. This is normal physiology, not medication failure. The medication continues preventing weight regain even after loss plateaus.

Can you lose 50 pounds on Zepbound?

Yes, if your starting weight supports it. A patient starting at 250 pounds who loses 20% of body weight will lose 50 pounds. The SURMOUNT-1 trial showed 15% to 25% total weight loss depending on dose, so 50+ pound losses are common in patients starting above 230 pounds.

What happens if I stop Zepbound after losing weight?

Most patients regain about two-thirds of lost weight within 52 weeks of stopping tirzepatide, based on the SURMOUNT-4 withdrawal trial (Aronne et al., JAMA, 2024). Continuing medication long-term is necessary to maintain weight loss for most patients.

How fast do you lose weight on compounded tirzepatide vs brand Zepbound?

Compounded tirzepatide contains the same active ingredient as brand-name Zepbound and produces comparable weight loss when dosed equivalently. The SURMOUNT trials used brand tirzepatide, but the mechanism of action is identical for compounded versions.

Is losing 2 pounds a week on Zepbound normal?

Yes. Two pounds per week is typical during the acceleration phase (weeks 12 to 40) and represents healthy, sustainable weight loss. Faster loss (3+ pounds per week sustained) may increase gallstone risk and should be discussed with your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet. 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised, Open-Label, Phase 3, Non-Inferiority Trial. The Lancet. 2021.
5. Blonde L et al. Real-World Evidence of Weight Loss in Patients Switching from Semaglutide to Tirzepatide. Journal of Clinical Endocrinology & Metabolism. 2024.
6. Wilding JPH et al. Weight Loss Composition and Protein Intake in Tirzepatide-Treated Patients: Post-Hoc Analysis of SURMOUNT-1. Diabetes, Obesity and Metabolism. 2024.
7. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
8. Garvey WT et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Nature Medicine. 2022.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
10. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
11. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. The Lancet. 2021.
12. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomised, Open-Label, Parallel-Group, Phase 3 Trial. The Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): A Randomised, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial. The Lancet. 2021.
14. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.